Amgen’s Immuno-Oncology Strategy Hinges On T-VEC’s Mechanism, Combinability

Awaiting FDA approval for monotherapy in metastatic melanoma, Amgen uses ASCO to launch new combination studies with Merck and Roche immune checkpoint inhibitors, adding to one ongoing with Bristol’s Yervoy.